Join Richmond Pharamcology at the 2nd DIA Cardiac Safety Workshop in Japan for our latest TQT Analysis in Japanese and Caucasian Volunteers

Posted:
16
August 2011

Richmond Pharmacology Ltd is proud to announce its participation in the �2nd DIA Cardiac Safety Workshop in Japan,� being held September 5-6, 2011 at Tower Hall Funabori in Tokyo, Japan. The meeting will address the key scientific, clinical and regulatory issues of implementation of ICH-E14 in Japan and bring together experts from multiple disciplines; intended to facilitate an open and productive dialogue between regulatory, industry and academic delegates.As a feature, the first ever formal Japanese Caucasian bridging TQT analysis will be presented by Dr Jorg Taubel, CEO and Principal Investigator of Richmond Pharmacology Ltd. The analysis was carried out jointly between the Department of Pharmacology of Toho University, the Cardiovascular Sciences Research Centre at St Georges University of London and Richmond Pharmacology Ltd. This groundbreaking presentation being held on Day 1, Session 3 from 17h00 to 17h30 promises to be an informative and insightful discussion relating to the recent implementation of ICH-E14.Having successfully completed in excess of 50 studies in Japanese subjects since 2002, many of which have already been used in regulatory submissions in Japan, Richmond Pharmacology Ltd is well positioned to conduct TQT Studies in Japanese subjects outside of Japan and for the conduct of TQT Bridging Studies in a mixed Japanese and Caucasian study populations. To learn more about our specialist expertise in Japanese Studies come meet our team at booth numbers 8-9, where Richmond Pharmacology Ltd will be happy to discuss our capabilities in more detail.If you are interested in attending the 2nd DIA Cardiac Safety Workshop in Japan, click here to register or contact a member of our business development team to arrange a meeting in person. We look forward to seeing you in Tokyo!

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more